Suppr超能文献

18F-FDG PET与皮质类固醇联合应用于未经组织病理学证实的深部原发性中枢神经系统淋巴瘤的诊断

Combined use of 18 F-FDG PET and corticosteroid for diagnosis of deep-seated primary central nervous system lymphoma without histopathological confirmation.

作者信息

Yamaguchi Shigeru, Hirata Kenji, Kaneko Sadahiro, Kobayashi Hiroyuki, Shiga Tohru, Kobayashi Kentaro, Onimaru Rikiya, Shirato Hiroki, Tamaki Nagara, Terasaka Shunsuke, Houkin Kiyohiro

机构信息

Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, 5 West 7, Kita-ku, 060-8638, Sapporo, Japan.

出版信息

Acta Neurochir (Wien). 2015 Feb;157(2):187-94. doi: 10.1007/s00701-014-2290-7. Epub 2014 Dec 10.

Abstract

BACKGROUND

Although histological diagnosis is indispensable in treating primary central nervous system lymphoma (PCNSL), we sometimes face an intractable situation in which tissue can be obtained only from a deep-seated brain lesion. In place of a histological diagnosis, the diagnostic adequacy of the combined use of 18 F-FDG PET and corticosteroid administration for PCNSL located in a deep-seated brain structure is reported.

METHODS

Patients with a deep-seated tumor were treated as having PCNSL without histological confirmation, based on the following criteria: (1) there was no evidence of systemic malignancy; (2) the tumor showed an extremely high FDG uptake relative to normal gray matter on pretreatment 18 F-FDG PET; (3) the tumor decreased in size 1 week after diagnostic therapy by corticosteroid administration on contrast-enhanced T1-weighted magnetic resonance imaging (MRI). FDG uptake of the lesion was evaluated by the maximum of standardized uptake values (SUVmax) and tumor-to-normal ratio of the SUV (T/N ratio). The extent of the tumor reduction was calculated by volumetric analysis for the treatment response to corticosteroid administration.

RESULTS

Ten patients (4 males and 6 females) matched these criteria. On pretreatment 18 F-FDG PET, mean SUVmax in the tumor was 24.8 (8.75-60.75), and mean T/N ratio was 3.24 (2.17-5.12). The extent of tumor volume reduction was shown to be 21 to 68 % 1 week after diagnostic therapy by corticosteroids. Mean total dose and duration of corticosteroids were 719 mg as prednisolone and 6.5 days, respectively. Nine patients achieved complete response and one patient achieved partial response on MRI after standard treatment for PCNSL with high-dose methotrexate and/or whole-brain irradiation.

CONCLUSION

Although the value of biopsy is universal, combining 18 F-FDG PET and corticosteroid administration is an important alternative method that may lead to the diagnosis of deep-seated PCNSLs in cases with intractable histopathological confirmations.

摘要

背景

虽然组织学诊断在原发性中枢神经系统淋巴瘤(PCNSL)的治疗中不可或缺,但我们有时会面临难以处理的情况,即只能从深部脑病变获取组织。本文报道了对于位于深部脑结构的PCNSL,联合使用18F-FDG PET和皮质类固醇给药的诊断充分性,以此替代组织学诊断。

方法

基于以下标准,将深部肿瘤患者在未进行组织学确诊的情况下视为患有PCNSL:(1)无全身恶性肿瘤证据;(2)在治疗前的18F-FDG PET上,肿瘤相对于正常灰质显示出极高的FDG摄取;(3)在对比增强T1加权磁共振成像(MRI)上,经皮质类固醇进行诊断性治疗1周后,肿瘤大小缩小。通过标准化摄取值最大值(SUVmax)和SUV的肿瘤与正常比值(T/N比值)评估病变的FDG摄取。通过体积分析计算皮质类固醇给药治疗反应的肿瘤缩小程度。

结果

10例患者(4例男性和6例女性)符合这些标准。在治疗前的18F-FDG PET上,肿瘤的平均SUVmax为24.8(8.75 - 60.75),平均T/N比值为3.24(2.17 - 5.12)。经皮质类固醇进行诊断性治疗1周后,肿瘤体积缩小程度为21%至68%。皮质类固醇的平均总剂量和持续时间分别为泼尼松龙719 mg和6.5天。在采用大剂量甲氨蝶呤和/或全脑照射对PCNSL进行标准治疗后,9例患者在MRI上达到完全缓解,1例患者达到部分缓解。

结论

虽然活检的价值是普遍认可的,但联合使用18F-FDG PET和皮质类固醇给药是一种重要的替代方法,在难以进行组织病理学确诊的情况下,可能有助于诊断深部PCNSL。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验